STRATA Skin Sciences (NASDAQ:SSKN) Stock Rating Lowered by Zacks Investment Research

STRATA Skin Sciences (NASDAQ:SSKN) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Thursday, Zacks.com reports.

According to Zacks, “Strata Skin Sciences, Inc. is a medical technology company which focused on the dermatology market. Its products include the XTRAC laser(R) and VTRAC(R) excimer lamp systems for treatment of psoriasis, vitiligo and other skin conditions as well as the MelaFind (R) system used for identification and management of melanoma skin cancer. Strata Skin Sciences, Inc., formerly known as MELA Sciences, Inc., is based in Horsham, Pennsylvania. “

Other research analysts also recently issued reports about the company. Oppenheimer initiated coverage on STRATA Skin Sciences in a report on Wednesday, November 20th. They set an “outperform” rating and a $7.00 price target on the stock. HC Wainwright reiterated a “buy” rating on shares of STRATA Skin Sciences in a research report on Monday, September 16th. ValuEngine cut STRATA Skin Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, November 14th. Finally, LADENBURG THALM/SH SH initiated coverage on STRATA Skin Sciences in a research report on Monday, December 9th. They set a “buy” rating and a $5.25 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. STRATA Skin Sciences currently has a consensus rating of “Buy” and an average target price of $5.40.

Shares of NASDAQ:SSKN opened at $2.14 on Thursday. The company has a quick ratio of 1.67, a current ratio of 1.97 and a debt-to-equity ratio of 0.21. STRATA Skin Sciences has a 1 year low of $1.65 and a 1 year high of $3.43. The stock’s fifty day moving average price is $2.24 and its 200-day moving average price is $2.29.

STRATA Skin Sciences (NASDAQ:SSKN) last announced its quarterly earnings results on Monday, November 18th. The medical device company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.02). The business had revenue of $7.48 million for the quarter, compared to the consensus estimate of $9.12 million. STRATA Skin Sciences had a negative net margin of 9.74% and a negative return on equity of 9.98%. On average, analysts forecast that STRATA Skin Sciences will post -0.11 EPS for the current year.

A number of institutional investors have recently bought and sold shares of the stock. Acadian Asset Management LLC increased its position in STRATA Skin Sciences by 35.2% during the second quarter. Acadian Asset Management LLC now owns 52,715 shares of the medical device company’s stock valued at $131,000 after acquiring an additional 13,716 shares during the last quarter. BlackRock Inc. increased its position in STRATA Skin Sciences by 33.5% during the second quarter. BlackRock Inc. now owns 82,972 shares of the medical device company’s stock valued at $207,000 after acquiring an additional 20,803 shares during the last quarter. Vanguard Group Inc. increased its position in STRATA Skin Sciences by 3.5% during the second quarter. Vanguard Group Inc. now owns 627,003 shares of the medical device company’s stock valued at $1,561,000 after acquiring an additional 21,000 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in STRATA Skin Sciences by 6.7% during the second quarter. Renaissance Technologies LLC now owns 1,100,116 shares of the medical device company’s stock valued at $2,739,000 after acquiring an additional 69,300 shares during the last quarter. Institutional investors own 26.57% of the company’s stock.

About STRATA Skin Sciences

STRATA Skin Sciences, Inc, a medical technology company, focuses on the therapeutic and aesthetic dermatology market. The company operates through three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment, and Dermatology Imaging. Its products include XTRAC laser and VTRAC excimer lamp systems used for the treatment of psoriasis, vitiligo, and other skin conditions; the STRATAPEN MicroSystems, a micropigmentation device; and Nordlys, a multi-technology aesthetic laser device for treating vascular and pigmented lesions.

See Also: Float

Get a free copy of the Zacks research report on STRATA Skin Sciences (SSKN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for STRATA Skin Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STRATA Skin Sciences and related companies with MarketBeat.com's FREE daily email newsletter.